Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Renalytix ( (GB:RENX) ) has issued an update.
Renalytix has submitted an application for CE Mark certification for its kidneyintelX.dkd test under the European Union In-Vitro Diagnostics Regulation. This move is driven by growing international strategic partner interest and discussions with a top global pharmaceutical company for potential use in a clinical trial and as a companion diagnostic. Achieving the CE Mark, expected in the first half of 2026, could open further commercial opportunities and solidify kidneyintelX.dkd’s position as a global precision medicine standard in chronic kidney disease.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has received FDA approval and Medicare reimbursement for its kidneyintelX.dkd test, which is commercially available in the United States.
Average Trading Volume: 3,722,894
Technical Sentiment Signal: Sell
Current Market Cap: £38.51M
See more insights into RENX stock on TipRanks’ Stock Analysis page.